Pfizer Inc
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 12, 2026), Pfizer Inc reported 18 stock positions worth $236.5 million. Its top holding was Oric Pharmaceuticals (ORIC) at 18.6% of the portfolio, followed by Arvinas (ARVN, 17.3%) and Celcuity (CELC, 14.7%). Compared with Q3 2025, it sold out of 3 and reduced 1. The biggest sale was an exit from Biontech SE-ADR (BNTX).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0000078003
- Portfolio Value
- $236.5M (Q4 2025)
- SEC Filing
- 0000078003-26-000013 ↗ filed Feb 12, 2026
Holdings Value
Holdings 18 stocks · $236.5M
| ORIC Oric Pharmaceuticals Inc. | 18.60% | 5,376,344 | $44.0M | No change |
| ARVN Arvinas Inc. | 17.34% | 3,457,815 | $41.0M | No change |
| CELC Celcuity Inc. | 14.74% | 349,406 | $34.8M | No change |
| WVE Wave Life Sciences Ltd. | 13.48% | 1,875,000 | $31.9M | No change |
| ALLO Allogene Therapeutics Inc. | 12.76% | 22,032,040 | $30.2M | No change |
| ZURA Zura Bio Ltd. | 6.58% | 2,970,022 | $15.6M | No change |
| PYXS Pyxis Oncology Inc. | 3.42% | 7,032,770 | $8.1M | No change |
| CRBU Caribou Biosciences Inc. | 3.15% | 4,690,431 | $7.5M | No change |
| CRDF Cardiff Oncology Inc. | 2.87% | 2,411,575 | $6.8M | No change |
| BHVN Biohaven Ltd. | 2.41% | 505,645 | $5.7M | No change |
| SPRO Spero Therapeutics Inc. | 2.33% | 2,362,348 | $5.5M | No change |
| NXTC Nextcure Inc. | 0.95% | 157,646 | $2.2M | No change |
| ZNTL Zentalis Pharmaceuticals Inc. | 0.54% | 953,834 | $1.3M | No change |
| QTTB Q32 Bio Inc. | 0.39% | 277,777 | $922K | No change |
| ANTX AN2 Therapeutics Inc. | 0.34% | 715,295 | $815K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.07% | 31,305 | $171K | No change |
| DNA Ginkgo Bioworks Holdings Inc. | 0.01% | 2,928 | $24K | No change |
| SENS Senseonics Holdings Inc. | 0.01% | 2,171 | $12K | Reduce -95.0% |
Portfolio Sells Q3 2025 → Q4 2025
Portfolio Buys Q3 2025 → Q4 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 17 | $170.4M | ALLO, CELC, ARVN, PYXS, WVE |
| Q1 2026 | 18 | $238.8M | ORIC, ALLO, ARVN, CELC, ZURA |
| Q4 2025 | 18 | $236.5M | ORIC, ARVN, CELC, WVE, ALLO |
| Q3 2025 | 21 | $437.5M | BNTX, ORIC, TRML, ARVN, ALLO |
| Q2 2025 | 21 | $576.2M | BNTX, ORIC, ARVN, ALLO, TRML |
| Q1 2025 | 21 | $500.8M | BNTX, ALLO, ORIC, ARVN, TRML |
| Q4 2024 | 23 | $2.6B | HLN, BNTX, ARVN, ALLO, ORIC |